Please use this identifier to cite or link to this item:
|Title:||Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.||Austin Authors:||Nguyen, Mike ;Segelov, Eva;Goldstein, David;Pavlakis, Nick;Shapiro, Jeremy;Price, Timothy J;Nagrial, Adnan;Chantrill, Lorraine;Leong, Trevor;Chen, John;Burge, Matt;Karapetis, Christos S;Chau, Ian;Lordick, Florian;Renouf, Daniel;Tebbutt, Niall C ;Roy, Amitesh C||Affiliation:||Department of Haematology and Oncology, The Queen Elizabeth Hospital/University of Adelaide, Adelaide, Australia..
Department of Medical Oncology, Prince of Wales Hospital, University of NSW, Sydney, Australia..
Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Australia..
Department of Cancer Care Services, Royal Brisbane Hospital, University of Queensland, Herston, Australia..
Olivia Newton-John Cancer Wellness and Research Centre
Department Medical Oncology, Wollongong Hospital, Illawarra Shoalhaven Local Health District, Australia..
Division of Radiation Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia..
Department of Medicine, Royal Marsden Hospital, Institute of Cancer Research, Surrey, London, UK..
Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney, Australia..
Cabrini Health, Monash University, Melbourne, Australia..
Department of Medical Oncology, Westmead & Blacktown Hospitals, University of Sydney, Sydney, Australia..
Department of Medical Oncology, School of Clinical Sciences, Monash University and Monash Health, Melbourne, Australia..
University Cancer Center Leipzig and Department of Oncology, Gastroenterology, Hepatology, Pneumology and Infectious Diseases, Leipzig University Medical Center, Leipzig, Germany..
Department of Medical Oncology, BC Cancer. Faculty of Medicine, University of British Columbia, Vancouver, Canada..
|Issue Date:||Jan-2022||metadata.dc.date:||2021||Publication information:||Expert Review of Anticancer Therapy 2022; 22(1): 39-51||Abstract:||Pancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localized and advanced pancreatic cancer and offers an expert opinion on current best practice. For patients with localized disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resectable, borderline resectable, and locally advanced disease. Advances in metastatic disease are discussed including cytotoxic chemotherapy, targeted therapies, and the role of genomic testing to identify patients with molecular alterations. Reviewed literature included journal publications, abstracts presented at major international oncology meetings, and ongoing clinical trials databases. Pancreatic cancer is a devastating diagnosis and despite recent advances has a very poor prognosis. Only a minority of patients, 20%, are diagnosed with potentially curable disease. The shifting paradigm toward neoadjuvant therapy may improve resectability and survival rates; however, robust evidence is required. Thus far, there has only been limited progress in advanced stage disease. Genomic testing may potentially identify more treatment targets although limited to small subgroups.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/30078||DOI:||10.1080/14737140.2022.2002689||ORCID:||0000-0003-3044-1707
|Journal:||Expert Review of Anticancer Therapy||PubMed URL:||34739362||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/34739362/||Type:||Journal Article||Subjects:||Pancreatic cancer
|Appears in Collections:||Journal articles|
Show full item record
checked on Jun 4, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.